GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HOOKIPA Pharma Inc (NAS:HOOK) » Definitions » PB Ratio
中文

HOOKIPA Pharma (HOOKIPA Pharma) PB Ratio

: 0.86 (As of Today)
View and export this data going back to 2019. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), HOOKIPA Pharma's share price is $0.7795. HOOKIPA Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was $0.91. Hence, HOOKIPA Pharma's PB Ratio of today is 0.86.

The historical rank and industry rank for HOOKIPA Pharma's PB Ratio or its related term are showing as below:

HOOK' s PB Ratio Range Over the Past 10 Years
Min: 0.38   Med: 1.03   Max: 3.74
Current: 0.86

During the past 7 years, HOOKIPA Pharma's highest PB Ratio was 3.74. The lowest was 0.38. And the median was 1.03.

HOOK's PB Ratio is ranked better than
83.59% of 1310 companies
in the Biotechnology industry
Industry Median: 2.38 vs HOOK: 0.86

During the past 12 months, HOOKIPA Pharma's average Book Value Per Share Growth Rate was -51.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -44.30% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of HOOKIPA Pharma was -25.90% per year. The lowest was -44.30% per year. And the median was -35.10% per year.

Back to Basics: PB Ratio


HOOKIPA Pharma PB Ratio Historical Data

The historical data trend for HOOKIPA Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 2.65 2.11 0.81 0.43 0.89

HOOKIPA Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.48 0.66 0.54 0.89

Competitive Comparison

For the Biotechnology subindustry, HOOKIPA Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HOOKIPA Pharma PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's PB Ratio falls into.



HOOKIPA Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

HOOKIPA Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.7795/0.908
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


HOOKIPA Pharma  (NAS:HOOK) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


HOOKIPA Pharma PB Ratio Related Terms

Thank you for viewing the detailed overview of HOOKIPA Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HOOKIPA Pharma (HOOKIPA Pharma) Business Description

Traded in Other Exchanges
N/A
Address
350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Executives
Reinhard Kandera director, officer: Chief Financial Officer C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Jorn Aldag director, officer: Chief Executive Officer C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Katia Schlienger officer: Chief Medical Officer 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Malte Peters director TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Timothy P. Reilly director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Igor Matushansky officer: Chief Medical Officer C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Sofinnova Capital Vi Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008
Christine D. Baker officer: Chief Business Officer C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Jean-charles Soria director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118
Anders Lilja officer: Sr. VP, Technical Development C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Klaus Orlinger officer: Sr. VP, Research C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Roman Necina officer: Chief Technology Officer C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Forbion Capital Fund Ii Cooperatief U.a. 10 percent owner C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016

HOOKIPA Pharma (HOOKIPA Pharma) Headlines

From GuruFocus